Indivior PLC (NASDAQ:INDV) Stock Has Average Target Price of $45.17 According to Brokerages

Shares of Indivior PLC (NASDAQ:INDV) have received a consensus recommendation of “Buy” from the seven research firms that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $45.17.

Several analysts have issued reports on the company. Craig Hallum restated a “buy” rating and set a $53.00 price objective on shares of Indivior in a research note on Tuesday, August 4th. Zacks Research upgraded Indivior from a “hold” rating to a “strong-buy” rating in a research report on Friday, October 2nd. Barclays decreased their price objective on shares of Indivior from $46.00 to $43.00 and set an “overweight” rating for the company in a report on Wednesday, August 5th. Finally, Weiss Ratings downgraded Indivior from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, September 24th.

Indivior Stock Performance

Shares of Indivior stock opened at $34.16 on Thursday. The firm has a market cap of $4.03 billion, a PE ratio of 12.24 and a beta of 0.87. The firm’s 50-day simple moving average is $36.13 and its 200-day simple moving average is $36.72. Indivior has a 1 year low of $23.72 and a 1 year high of $42.81.

Indivior (NASDAQ:INDV) last posted its quarterly earnings results on Tuesday, June 30th. The company reported $5.75 EPS for the quarter. The business had revenue of $343.00 million during the quarter. Indivior had a negative return on equity of 283.11% and a net margin of 26.65%. On average, equities analysts predict that Indivior will post 3.66 earnings per share for the current year.

Indivior Dividend Announcement

The business also recently disclosed a special dividend, which will be paid on Friday, November 6th. Investors of record on Friday, October 30th will be given a dividend of $8.13 per share. The ex-dividend date is Friday, October 30th.

Insider Transactions at Indivior

In related news, CAO Woodrow D. Anderson acquired 1,500 shares of the stock in a transaction that occurred on Thursday, August 27th. The stock was purchased at an average cost of $35.69 per share, for a total transaction of $53,535.00. Following the purchase, the chief accounting officer directly owned 27,638 shares in the company, valued at $986,400.22. This represents a 5.74% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. 0.74% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Indivior

Hedge funds have recently added to or reduced their stakes in the stock. Caitong International Asset Management Co. Ltd grew its position in shares of Indivior by 72.7% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,093 shares of the company’s stock worth $39,000 after acquiring an additional 460 shares during the last quarter. Rockefeller Capital Management L.P. increased its holdings in shares of Indivior by 512.4% in the 4th quarter. Rockefeller Capital Management L.P. now owns 1,286 shares of the company’s stock worth $46,000 after acquiring an additional 1,076 shares during the period. TD Waterhouse Canada Inc. bought a new stake in Indivior in the 2nd quarter valued at about $63,000. GAMMA Investing LLC bought a new stake in Indivior in the 2nd quarter valued at about $66,000. Finally, Farther Finance Advisors LLC lifted its position in Indivior by 716.2% in the 3rd quarter. Farther Finance Advisors LLC now owns 3,624 shares of the company’s stock valued at $130,000 after purchasing an additional 3,180 shares during the last quarter. 60.33% of the stock is currently owned by institutional investors.

Indivior Company Profile

Indivior PLC (NASDAQ: INDV) is a specialty pharmaceutical company focused on developing and commercializing treatments for substance use disorders and serious mental health conditions. The company’s primary focus is opioid use disorder, with products designed to support patients through medication-assisted treatment and recovery.

Indivior’s portfolio includes Sublocade, an extended-release injectable formulation of buprenorphine; Suboxone, a buprenorphine and naloxone product available in sublingual formulations; and Perseris, an extended-release injectable formulation of risperidone for schizophrenia.